Sign in

Dominic Risso-Gill

Managing Director in the chemicals group at Cowen Inc.

Dominic Risso-Gill is a Managing Director in the chemicals group at Piper Sandler, offering deep expertise in M&A within the chemicals and related materials sectors. He has advised major global companies including INEOS, Dow, and Arkema, and played a key role in landmark transactions such as Carlyle’s acquisition of AkzoNobel’s Specialty Chemicals business, the largest-ever LBO in Europe. With over 15 years in financial services, he previously held senior positions at The Valence Group and Credit Suisse, building a robust track record across more than 50 M&A engagements totaling values from $100 million to over $10 billion. Risso-Gill earned a first-class bachelor’s degree with honors in English Language and Literature from the University of Leeds, underscoring his strong academic foundation.

Dominic Risso-Gill's questions to Altimmune (ALT) leadership

Question · Q2 2025

Dominic Risso-Gill of Piper Sandler Companies questioned if any alcohol consumption data was collected in the IMPACT NASH study that could help de-risk the RECLAIM and RESTORE trials for AUD and ALD. He also asked about the readout timing and the criteria for advancing these programs to Phase 3.

Answer

Chief Medical Officer Dr. M. Scott Harris stated that the IMPACT data is still being analyzed for alcohol measures and updates will be provided later. He expressed confidence in the AUD/ALD programs based on strong preclinical data and the known effects of GLP-1 agents, adding that Phase 3 plans will be determined after meeting with the FDA post-Phase 2.

Ask follow-up questions

Fintool

Fintool can predict Altimmune logo ALT's earnings beat/miss a week before the call

Dominic Risso-Gill's questions to NEKTAR THERAPEUTICS (NKTR) leadership

Question · Q1 2025

Dominic Risso-Gill of TD Cowen inquired about the efficacy benchmarks for advancing REZPEG in atopic dermatitis to Phase III, the number of doses planned for the pivotal study, and expectations for the placebo response rate in the REZOLVE-AD trial.

Answer

Jonathan Zalevsky, an executive, stated that success would involve replicating Phase I data and achieving efficacy at least comparable to DUPIXENT. The goal is to identify a single dose for Phase III. He added that Nektar hopes for a placebo response lower than the 47% seen in Phase Ib, aided by measures like reduced U.S. site enrollment and using experienced dermatologists.

Ask follow-up questions

Fintool

Fintool can predict NEKTAR THERAPEUTICS logo NKTR's earnings beat/miss a week before the call

Let Fintool AI Agent track Dominic Risso-Gill for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free